1. Home
  2. QNRX vs BJDX Comparison

QNRX vs BJDX Comparison

Compare QNRX & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

N/A

Current Price

$4.54

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Logo Bluejay Diagnostics Inc.

BJDX

Bluejay Diagnostics Inc.

N/A

Current Price

$0.86

Market Cap

961.6K

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QNRX
BJDX
Founded
2018
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
961.6K
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
QNRX
BJDX
Price
$4.54
$0.86
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $21.83
N/A
AVG Volume (30 Days)
60.3K
★ 968.9K
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 86.65
EPS
★ N/A
N/A
Revenue
N/A
★ $249,040.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$0.63
52 Week High
$41.80
$7.00

Technical Indicators

Market Signals
Indicator
QNRX
BJDX
Relative Strength Index (RSI) 30.94 41.68
Support Level $4.23 $0.82
Resistance Level $5.11 $1.06
Average True Range (ATR) 0.53 0.06
MACD -0.34 0.01
Stochastic Oscillator 5.06 19.50

Price Performance

Historical Comparison
QNRX
BJDX

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

Share on Social Networks: